Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database

To evaluate the persistence and adherence of subcutaneous biologics in patients with psoriatic arthritis (PsA). Psoriatic arthritis patients who initiated adalimumab, certolizumab pegol, etanercept, golimumab or secukinumab between 15 January 2016 and 31 July 2017 were identified in the Truven Datab...

Full description

Saved in:
Bibliographic Details
Published inJournal of comparative effectiveness research Vol. 8; no. 8; pp. 607 - 621
Main Authors Oelke, Kurt R, Chambenoit, Olivier, Majjhoo, Amar Q, Gray, Stephani, Higgins, Kate, Hur, Peter
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.06.2019
Subjects
Arthritis
biologics
Clinical medicine
Comorbidity
Costs
Health care policy
Monoclonal antibodies
Patients
Pharmacy
Psoriasis
Psoriatic arthritis
Studies
TNF inhibitors
treatment patterns
Tumor necrosis factor-TNF
United States > US
biologics
treatment patterns
psoriatic arthritis
Online AccessGet full text

Cover

More Information
Summary:To evaluate the persistence and adherence of subcutaneous biologics in patients with psoriatic arthritis (PsA). Psoriatic arthritis patients who initiated adalimumab, certolizumab pegol, etanercept, golimumab or secukinumab between 15 January 2016 and 31 July 2017 were identified in the Truven Databases. Outcomes included discontinuation rate, persistence and adherence over 12 months. Of 1558 patients included, the 12-month discontinuation rate was lowest with secukinumab (36.5%), followed by adalimumab, golimumab, etanercept and certolizumab pegol (42.6-51.6%). Mean persistence ranged from 240.7 (certolizumab pegol) to 282.8 days (secukinumab). The mean proportion of days covered was highest with secukinumab (0.67) and lowest with certolizumab pegol (0.49). Patients who initiated secukinumab had the lowest discontinuation rate and highest persistence and adherence over 12 months.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2019-0023